In contrast, high PK activity or pharmacological activation of PKM2 was shown to inhibit aerobic glycolytic phenotypes and tumour growth26, 27, 28, underscoring the importance of identifying endogenous regulators of PKM2 activity in cancer. The gene discussed is PKM; the disease is neoplasm.